Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells
/in Breast Cancer, Dendritic Cells, International Publications, Ovarian Cancer /von 2000-11-01 / Blood 2000 Nov;96(9):3102-8The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor
/in Hyperthermia, International Publications /von 2000-08-01 / Eur. J. Immunol. 2000 Aug;30(8):2211-5Increase in the immunostimulatory effect of dendritic cells by pulsing with serum derived from pancreatic and colorectal cancer patients
/in International Publications, Pancreatic Cancer /von 2000-08-01 / Int J Colorectal Dis 2000 Aug;15(4):197-205External beam radiotherapy and hyperthermia in the treatment of patients with locally advanced prostate carcinoma
/in Hyperthermia, International Publications, Prostate Cancer /von 2000-07-15 / Cancer 2000 Jul;89(2):399-403Increase of the immunostimulatory effect of dendritic cells by pulsing with CA 19-9 protein
/in International Publications, Pancreatic Cancer /von 2000-07-01 / J. Immunother. 2000 Jul-Aug;23(4):464-72Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways
/in Hyperthermia, International Publications /von 2000-06-05 / J. Exp. Med. 2000 Jun;191(11):1957-64Use of mild, whole body hyperthermia in cancer therapy
/in Hyperthermia, International Publications /von 2000-05-01 / Immunol. Invest. 2000 May;29(2):139-42Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group
/in Cervical Cancer, Colorectal Cancer, Hyperthermia, International Publications /von 2000-04-01 / Lancet 2000 Apr;355(9210):1119-25HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine
/in Hyperthermia, International Publications /von 2000-04-01 / Nat. Med. 2000 Apr;6(4):435-42IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de